Bob Edmonston
About Bob Edmonston
Bob Edmonston is the Executive Director at Alkermes, where he leads CMC efforts and manages a department of 13 employees. He has held multiple leadership roles at Alkermes since 2002 and has a background in Organic Chemistry from the University of Wisconsin-Madison.
Company
Bob Edmonston is currently employed at Alkermes, where he holds the position of Executive Director. Alkermes is involved in the development of innovative drugs aimed at tackling mental health disorders, addiction, and other severe conditions.
Title
Bob Edmonston serves as the Executive Director at Alkermes. In this capacity, he oversees various strategic initiatives involving drug substance and drug product development, product design, and analytics to support both development and commercial programs.
Career Background
Bob Edmonston has an extensive career background at Alkermes. He previously served in various roles including Senior Director, CMC Leadership (2020-2021), Director, Chemical Development (2011-2019), Associate Director, Product Development (2007-2011), and Manager & Supervisor roles in Analytical and Quality Control (2002-2007). Prior to joining Alkermes, Edmonston was an Associate Group Leader at PPD from 1999 to 2002.
Education and Expertise
Bob Edmonston studied at the University of Wisconsin-Madison, where he earned his MS in Organic Chemistry from 1997 to 1999. Before that, he attended Earlham College from 1993 to 1996. His academic background has provided him with a strong foundation in chemical and pharmaceutical sciences.
Leadership and Initiatives
At Alkermes, Bob Edmonston chairs a cross-functional Pharmaceutical Development Forum for CMC teams to discuss program challenges and align on development strategy. As a member of the CMC Governance Board, he reviews program Stage Gates and evaluates key risks and mitigations. He leads the CMC efforts for the nemvaleukin alfa program, an immuno-oncology biologic currently in Phase 3, and manages a department of 13 employees through NDA/BLA submissions. Additionally, Edmonston acts as the primary liaison with Legal, Finance, and Strategic Sourcing for the broader Pharmaceutical Development organization, driving strategic initiatives related to drug substance and product development.